Atidortoxumab

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NameAtidortoxumab

Drug Alias NameASN-1

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human

Mechanisms of ActionAnti-hly

TargetsAlpha-hemolysin

Therapy Area/IndicationsPneumonia, Ventilator-AssociatedPneumonia, Staphylococcal

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCzechiaUnited StatesUkraine +[16]

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesArsanis Biosciences

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesArsanis Inc

Active IndicationsN/A

Inactive IndicationsPneumonia, Ventilator-AssociatedPneumonia, Staphylococcal

ATC CodeN/A